Eli Lilly CDR (CAD Hedged)
- Country
- πΊπΈUnited States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study to Evaluate the Effect of Food on LY2216684
- First Posted Date
- 2011-07-08
- Last Posted Date
- 2018-11-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT01389765
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daytona Beach, Florida, United States
A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin
- Conditions
- Solid TumorLymphoma, Malignant
- Interventions
- First Posted Date
- 2011-07-06
- Last Posted Date
- 2020-07-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 13
- Registration Number
- NCT01388335
- Locations
- π«π·
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France
A Study of LY2979165 in Healthy Subjects
- First Posted Date
- 2011-06-28
- Last Posted Date
- 2012-06-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 102
- Registration Number
- NCT01383967
- Locations
- πΈπ¬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, Singapore
A Study of LY2216684 in Healthy Participants
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: Placebo-matching LY2216684Drug: Placebo-matching alcoholic beverageDrug: Alcoholic beverage
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT01380691
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Evansville, Indiana, United States
A Study of LY2484595 in Japanese Subjects
- First Posted Date
- 2011-06-17
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 165
- Registration Number
- NCT01375075
- Locations
- π―π΅
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan
A Comparison of LY2963016 to a Basal Insulin After a Single Dose in Healthy Subjects
- First Posted Date
- 2011-06-15
- Last Posted Date
- 2014-10-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT01374178
- Locations
- πΈπ¬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, Singapore
A Study of LY2216684 in Healthy Females
- Conditions
- Depressive Disorder, Major
- Interventions
- First Posted Date
- 2011-06-15
- Last Posted Date
- 2018-10-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 20
- Registration Number
- NCT01373931
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
- Conditions
- NeoplasmsNeoplasm MetastasisPancreatic Cancer
- Interventions
- First Posted Date
- 2011-06-14
- Last Posted Date
- 2018-05-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 170
- Registration Number
- NCT01373164
- Locations
- πΊπΈ
Florida Hospital Tampa HPG and Foregut Surgery, Tampa, Florida, United States
πΊπΈIngalls Memorial Hospital, Harvey, Illinois, United States
πΊπΈSeattle Cancer Care Alliance, Seattle, Washington, United States
Single Dose Study in Healthy Participants to Investigate the Safety and Absorption of LY2584702
- Conditions
- Healthy Participants
- Interventions
- Drug: LY2584702 Reference FormulationDrug: PlaceboDrug: LY2584702 Test Formulation
- First Posted Date
- 2011-06-13
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 29
- Registration Number
- NCT01372085
- Locations
- πΈπ¬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, Singapore
A Study of LY2216684 in Participants With Major Depression Disorder
- First Posted Date
- 2011-06-10
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 288
- Registration Number
- NCT01370499
- Locations
- π―π΅
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan